Target intelligence / Profile preview

Ribosomal protein L36a-like (RPL36AL)

Target
RPL36AL
Molecular classification
Ribosomal protein (component of the large 60S ribosomal subunit), Structural protein, L44E (L36AE) family of ribosomal proteins
01

Overview

Ribosomal protein L36a-like (RPL36AL) is a structural protein component of the large 60S subunit of cytoplasmic ribosomes, the organelles responsible for protein synthesis[4][5][7]. The protein is highly similar in sequence to yeast ribosomal protein L44 and belongs to the L44E (L36AE) family of ribosomal proteins[4][5]. RPL36AL is encoded by a protein-coding gene that lacks introns in its coding regions, which likely resulted from retrotransposition of its X-linked homolog[2][10]. RPL36AL and its close paralog, RPL36A, encode nearly identical proteins but are distinct genes[5][7]. RPL36AL is ubiquitously expressed and is important for the functioning of the ribosome[2]. While mutations or dysfunction in ribosomal proteins may be implicated in some diseases through disruption of protein synthesis (notably Diamond-Blackfan anemia and rare cancer associations), RPL36AL itself is not currently considered a direct drug target or therapeutic receptor/enzyme/transporter[7]. There is no evidence of direct safety concerns, mechanism-based drug interactions, or biomarker utility related to this protein. RPL36AL is mainly relevant as a basic ribosomal protein contributing to core cell biology rather than as a regulatory target or therapeutic intervention point.

Other names
Ribosomal protein L36a-likeRPL36ALRibosomal protein eL42-like60S ribosomal protein L36a-likeLarge ribosomal subunit protein eL42-likeRPL36ARPL36AP42RPL36A_18_1363HL44Ribosomal protein L36a pseudogene 42
02

Mechanism of action

Not applicable; there are currently no drugs known to target this protein specifically[7].

03

Biological functions

Structural constituent of ribosomeTranslation (protein synthesis)May be involved upstream of or within response to retinoic acid (predicted)
04

Disease associations

Jejunal cancerDiamond-Blackfan anemiaThere is no robust evidence it serves as a direct oncogenic driver or primary disease target; the association is through ribosomal dysfunction.

Beyond the preview

Go deeper on Ribosomal protein L36a-like (RPL36AL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L36a-like (RPL36AL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call